US4031223A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Trifluoromethylthio derivatives of cyproheptadine
Assignee: Merck and Co Inc
•
Filing: 1975-12-22
•
Granted: 1977-06-21
•
Expires: 1995-12-22
Abstract
Abstract Cyproheptadine derivatives substituted with a trifluoromethylthio group in one of the benzo rings and certain derivatives thereof are potent antipsychotic agents, with a low propensity to induce extrapyramidal side effects experienced with most major tranquilizers, and platelet aggregation inhibitors useful as antithrombotic agents. The antipsychotic activity resides in the levorotatory enantiomer whereas both enantiomers are platelet aggregation inhibitors. The novel compounds are prepared by treatment of the corresponding iodo compound with trifluoromethylthiocopper formed from bis-(trifluoromethylthio)mercury and copper powder.
Inventors
- 👤 David C. Remy
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:28
CPC Classifications
C; C07; C07D; C07D211/00; C07D211/04; C07D211/68; C07D211/70; A; A61; A61P; A61P25/00; A61P25/18; A61P7/00; A61P7/02; C07D211/06; C07D211/08; C07D211/18; C07D211/20; C07D211/22
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
25 words
A levorotatory or dextrorotatory enantiomer of a compound of structural formula: ##STR4## or pharmaceutically acceptable salt thereof, wherein R is hydrogen, fluoro or lower alkyl.
Claim 2
Dependent Claim
25 words
A levorotatory or dextrorotatory enantiomer of a compound of structural formula: ##STR4## or pharmaceutically acceptable salt thereof, wherein R is hydrogen, fluoro or lower alkyl.
Claim 3
Dependent Claim
16 words
The compound of claim 1 which the levoroatory enantiomer of 1-methyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine or pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
17 words
The compound of claim 1, which is the dextrorotatory enantiomer of 1-methyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine or pharmaceutically acceptable salt thereof.
Claim 5
Independent Claim
39 words
A method of treating psychoses which comprises the administration to a patient in need of such treatment an effective amount of a compound of formula: ##STR5## or pharmaceutically acceptable salt thereof wherein R is hydrogen, fluoro, or lower alkyl.
Claim 6
Independent Claim
39 words
A method of treating psychoses which comprises the administration to a patient in need of such treatment an effective amount of a compound of formula: ##STR5## or pharmaceutically acceptable salt thereof wherein R is hydrogen, fluoro, or lower alkyl.
Claim 7
Dependent Claim
19 words
The method of claim 4 wherein the compound is the levorotatory enantiomer of 1-methyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine or pharmaceutically acceptable salt thereof.
Claim 8
Independent Claim
39 words
A method of treating thrombosis which comprises the administration, to a patient in need of such treatment, an effective amount of a compound of formula: ##STR6## or pharmaceutically acceptable salt thereof, wherein R is hydrogen, fluoro, or lower alkyl.
Claim 9
Independent Claim
39 words
A method of treating thrombosis which comprises the administration, to a patient in need of such treatment, an effective amount of a compound of formula: ##STR6## or pharmaceutically acceptable salt thereof, wherein R is hydrogen, fluoro, or lower alkyl.
Claim 10
Dependent Claim
15 words
The method of claim 6, wherein the compound is 1-methyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine or pharmaceutically acceptable salt thereof.
Claim 11
Dependent Claim
34 words
A pharmaceutical composition in unit dosage form comprising a pharmaceutical carrier and an effective amount of a compound of formula: ##STR7## or pharmaceutically acceptable salt thereof, wherein R is hydrogen, fluoro, or lower alkyl.
Claim 12
Dependent Claim
34 words
A pharmaceutical composition in unit dosage form comprising a pharmaceutical carrier and an effective amount of a compound of formula: ##STR7## or pharmaceutically acceptable salt thereof, wherein R is hydrogen, fluoro, or lower alkyl.
Claim 13
Dependent Claim
16 words
The pharmaceutical composition of claim 8, wherein the compound is 1-methyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine or pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
US3851059A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-06-20 | 1980-12-20 | 1981-06-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-06-20 | 1984-12-20 | 1985-06-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-06-20 | 1988-12-20 | 1989-06-21 | $7700.00 | Window Closed / Lapsed |